Targeted caspofungin prophylaxis for invasive aspergillosis in high-risk liver transplant recipients, a single-center experience.
Fungal infection
aspergillosis
caspofungin
echinocandin
liver transplantation
prophylaxis
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
04
11
2020
received:
06
09
2020
accepted:
03
01
2021
pubmed:
16
1
2021
medline:
23
9
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
Invasive aspergillosis (IA) is a rare but highly lethal complication after orthotopic liver transplantation (OLT). Targeted antifungal prophylaxis has been proposed as a strategy to prevent IA among orthotopic liver transplant recipient (OLTr), but limited data are available to support its efficacy. We conducted a single-center, retrospective, before and after cohort study, comparing IA incidences among OLTr who did not receive antifungal prophylaxis after transplantation (cohort 1) to OLTr who received targeted antifungal prophylaxis after liver transplantation (cohort 2). Patients in cohort 2 received caspofungin prophylaxis if they presented one of the following risk factors: retransplantation, acute liver failure, dialysis, or Aspergillus colonization prior to transplantation. The primary outcome was IA at 90 days after transplantation. A total of 391 OLTr were included in the study; 181 patients in the cohort 1 (no prophylaxis) and 210 patients in the cohort 2 (targeted prophylaxis). Among patients in cohort 2, 19% (40/ 210) were considered at high risk for IA and 85% (34/40) of those received caspofungin prophylaxis. The incidence of IA at 90 days was 3.3% (6/ 181) and 0.5% (1/ 210), in cohort 1 and 2, respectively (OR 0.14; 95%CI 0.01-0.83; P = .03). Ninety-day mortality was similar among the two cohorts (3.9% (7/181) and 2.4% (5/210) in cohort 1 and 2, respectively (OR 0.61; 95% 0.18-1.93; P = .40)). The 90-day mortality among the OLTs with IA was 71% (5/7). Targeted caspofungin prophylaxis was associated with lower rate of IA.
Sections du résumé
BACKGROUND
BACKGROUND
Invasive aspergillosis (IA) is a rare but highly lethal complication after orthotopic liver transplantation (OLT). Targeted antifungal prophylaxis has been proposed as a strategy to prevent IA among orthotopic liver transplant recipient (OLTr), but limited data are available to support its efficacy.
METHOD
METHODS
We conducted a single-center, retrospective, before and after cohort study, comparing IA incidences among OLTr who did not receive antifungal prophylaxis after transplantation (cohort 1) to OLTr who received targeted antifungal prophylaxis after liver transplantation (cohort 2). Patients in cohort 2 received caspofungin prophylaxis if they presented one of the following risk factors: retransplantation, acute liver failure, dialysis, or Aspergillus colonization prior to transplantation. The primary outcome was IA at 90 days after transplantation.
RESULTS
RESULTS
A total of 391 OLTr were included in the study; 181 patients in the cohort 1 (no prophylaxis) and 210 patients in the cohort 2 (targeted prophylaxis). Among patients in cohort 2, 19% (40/ 210) were considered at high risk for IA and 85% (34/40) of those received caspofungin prophylaxis. The incidence of IA at 90 days was 3.3% (6/ 181) and 0.5% (1/ 210), in cohort 1 and 2, respectively (OR 0.14; 95%CI 0.01-0.83; P = .03). Ninety-day mortality was similar among the two cohorts (3.9% (7/181) and 2.4% (5/210) in cohort 1 and 2, respectively (OR 0.61; 95% 0.18-1.93; P = .40)). The 90-day mortality among the OLTs with IA was 71% (5/7).
CONCLUSION
CONCLUSIONS
Targeted caspofungin prophylaxis was associated with lower rate of IA.
Substances chimiques
Caspofungin
F0XDI6ZL63
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13568Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Pappas P, Alexander B, Andes D, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-1111. https://doi.org/10.1086/651262
Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220-229. https://doi.org/10.1111/j.1399-3062.2010.00492.x
Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation. 1990s;64(5):716-720. https://doi.org/10.1097/00007890-199709150-00009
Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. 2002;74(5):688-695. https://doi.org/10.1097/00007890-200209150-00017
Fortún J, Martín-Dávila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87(3):424-435. https://doi.org/10.1097/TP.0b013e3181932e76
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18(1):44-69. https://doi.org/10.1128/CMR.18.1.44-69.2005
Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36(1):46-52. https://doi.org/10.1086/345441
Husain S, Silveira FP, Azie N, Franks B, Horn D. Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance(R) registry analysis. Med Mycol. 2017;55(3):269-277. https://doi.org/10.1093/mmy/myw086
Neofytos D, Chatzis O, Nasioudis D, et al. Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study. Transpl Infect Dis. 2018;20(4):e12898. https://doi.org/10.1111/tid.12898
Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation. 2001;71(7):910-913. https://doi.org/10.1097/00007890-200104150-00016
Fortún J, Martín-Dávila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8(11):1065-1070. https://doi.org/10.1053/jlts.2002.36239
Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl. 2007;13(12):1743-1750. https://doi.org/10.1002/lt.21331
Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996;62(7):926-934. https://doi.org/10.1097/00007890-199610150-00010
Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12(5):850-858. https://doi.org/10.1002/lt.20690
Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004;(3):CD004291. https://doi.org/10.1002/14651858.CD004291.pub2
Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 2006;25(9):549-561. https://doi.org/10.1007/s10096-006-0182-3
San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation. 2011;92(3):346-350. https://doi.org/10.1097/TP.0b013e3182247bb4
Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):228-241. https://doi.org/10.1111/ajt.12115
Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13544. https://doi.org/10.1111/ctr.13544
Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003;52(5):813-819. https://doi.org/10.1093/jac/dkg450
Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl. 2005;11(6):656-662. https://doi.org/10.1002/lt.20365
Saliba F, Delvart V, Ichaï P, et al. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients. Med Mycol. 2013;51(2):155-163. https://doi.org/10.3109/13693786.2012.701765
Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant. 2015;15(1):180-189. https://doi.org/10.1111/ajt.12993
Balogh J, Gordon Burroughs S, Boktour M, et al. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. Liver Transpl. 2016;22(2):163-170. https://doi.org/10.1002/lt.24365
Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2013;96(6):573-578. https://doi.org/10.1097/TP.0b013e31829d674f
Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758-2764. https://doi.org/10.1111/ajt.12963
Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60(7):997-1006. https://doi.org/10.1093/cid/ciu1128
Fortún J, Muriel A, Martín-Dávila P, et al. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis. Liver Transpl. 2016;22(4):427-435. https://doi.org/10.1002/lt.24391
De Pauw B, Walsh T, Donnelly J, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821. https://doi.org/10.1086/588660
Ranganathan P, Aggarwal R, Pramesh CS. Common pitfalls in statistical analysis: odds versus risk. Perspect Clin Res. 2015;6(4):222-224. https://doi.org/10.4103/2229-3485.167092
Williamson T, Eliasziw M, Fick GH. Log-binomial models: exploring failed convergence. Emerg Themes Epidemiol. 2013;10(1):14. https://doi.org/10.1186/1742-7622-10-14
Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol. 1998;27(1):91-95. https://doi.org/10.1093/ije/27.1.91
Castroagudı́n JF, Pontón C, Bustamante M, et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc. 2005;37(9):3965-3967. https://doi.org/10.1016/j.transproceed.2005.10.043
Kang W-H, Song G-W, Lee S-G, et al. A multicenter, randomized, open-label study to compare micafungin with fluconazole in the prophylaxis of invasive fungal infections in living-donor liver transplant recipients. J Gastrointest Surg. 2020;24(4):832-840. https://doi.org/10.1007/s11605-019-04241-w